WealthSource Partners’s Biolase, Inc. BIOL Stock Holding History

WealthSource Partners’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-6	Closed	-$13K	–	502
2021 Q1	$13K	Buy	+6	New	+$14.7K	﹤0.01%	432

Other funds holding BIOL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

WealthSource Partners's BIOL Position: Q2 2021 in Review

WealthSource Partners sold out of Biolase, Inc. (BIOL) in Q2 2021, closing a stake of 6 shares — an estimated $13K sold.

WealthSource Partners first reported a position in BIOL in Q1 2021 and held it in 1 quarter. The position peaked at $13K in Q1 2021. 31 funds tracked by Wall St. Rank hold BIOL as of Q2 2021.

WealthSource Partners reported no remaining Biolase, Inc. position as of Q2 2021 after selling out during the quarter.
WealthSource Partners sold 6 Biolase, Inc. shares in Q2 2021, an estimated $13K.
WealthSource Partners first reported a position in Biolase, Inc. in Q1 2021 and held it in 1 quarter.
WealthSource Partners's Biolase, Inc. position peaked at $13K in Q1 2021.
31 funds tracked by Wall St. Rank held Biolase, Inc. as of Q2 2021.

Based on WealthSource Partners's 13F filing for Q2 2021, filed 18 Nov 2021.